STOCKHOLDERS’ DEFICIT (Details Narrative) - USD ($)	1 Months Ended	2 Months Ended	3 Months Ended
STOCKHOLDERS’ DEFICIT (Details Narrative) - USD ($)	Feb. 10, 2021	Mar. 15, 2022	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Class of Stock [Line Items]
Common Stock, Shares Authorized			200,000,000		200,000,000
Common Stock, Par or Stated Value Per Share			$ 0.0001		$ 0.0001
Common Stock Description			All common stock shares have equal voting rights, are non-assessable and have one vote per share. Voting rights are not cumulative and, therefore, the holders of more than 50% of the common stock could, if they choose to do so, elect all of the directors of the Company, subject to the rights of the preferred stockholders
Debt conversion, converted instrument, shares issued			2,000,000	3,768,188
Debt conversion, converted instrument, amount			$ 53,610	$ 463,758
Options granted, exercise price			$ 0.12
Unrecognized compensation expense			$ 1,017,335
Stock based compensation			$ 250,139	382,473
Common stock authorized under plan			13,000,000
Shares issued price per share	$ 0.0001
Number of shares warrant increased		15,000,050
Proceeds from related party debt			$ 100,000
Exercise price		$ 0.01
Warrant Exercisable			18,786,716
Intrinsic value of warrants			$ 362,422
Weighted average remaining contractual life of warrants outstanding			3 years 3 months 21 days
Letter Agreement [Member]
Class of Stock [Line Items]
Number of shares warrant increased	3,500,000
Proceeds from related party debt	$ 1,207,500
Equity Option [Member]
Class of Stock [Line Items]
Options granted				250,000
Options granted, exercise price				$ 0.12
Vesting period				10 years
Value of option				$ 12,450
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock description			Effective May 3, 2018, the Company’s Board of Directors authorized and designated 75 shares of the Company’s Preferred Stock as Series A Preferred Stock. Each share of the Series A Preferred Stock is entitled to a liquidation preference of $1,000 per share and is convertible into 1,000 shares of the Company’s common stock. The holders of a majority of the Series A Preferred Stock are entitled to elect up to four (4) directors to the Company’s board of directors and have preferential rights in regard to the election of Series A directors. In all other voting matters, the holders of Series A Preferred Stock are entitled to cast 1,000 votes per share
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock description			Effective May 3, 2018, the Company’s Board of Directors authorized and designated 75 shares of the Company’s Preferred Stock as Series B Preferred Stock. Each share of the Series B Preferred Stock is entitled to a liquidation preference of $1,000 per share and is convertible into 1,000 shares of the Company’s common stock. The holders of a majority of the Series B Preferred Stock are entitled to elect up to three (3) directors to the Company’s board of directors and have preferential rights in regard to the election of Series B directors. In all other voting matters, the holders of Series B Preferred Stock are entitled to cast 1,000 votes per share

NEUROPATHIX, INC. 10-Q